AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors

PRESS RELEASEAB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF ...
Business Insider

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, December 18, 2025, 7.15pm CET AB Science SA (Euronext - FR0010557264 - AB) ...
WRIC

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

AB Science SA (Euronext - FR0010557264 - AB) announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the ...
CNN

AB Science announces that the European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted its phase 3 study results with masitinib in severe ...

The European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted AB Science phase 3 study AB07015 results with masitinib in severe asthma to be delivered as a late ...
Cantech Letter

Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB)

About Stonegate Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies.
Yahoo Finance

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid ...

AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA The fourth ...
Taiwan News

AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function

AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of a new article on the preprint platform MedRxiv, presenting a post-hoc subgroup analysis of the phase 2b/3 AB10015 study ...
Seeking Alpha

AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in ...
Yahoo Finance

AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041

MASITINIB HAS UNIQUE AND COMPETITIVE POSITIONING IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS DUE TO ITS DISTINCTIVE SAFETY AND EFFICACY PROFILE AND MECANISM OF ACTIONS TARGETING BOTH MICROGLIA AND MAST ...